Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Mol Oncol. 2022 Apr;16(8):1714-1727. doi: 10.1002/1878-0261.13194. Epub 2022 Feb 28.
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is often highly expressed in non-small cell lung cancer (NSCLC). Through its target genes, NRF2 enhances cancer progression and chemo/radioresistance, leading to a poorer prognosis in patients with high NRF2 expression. In this study, we identified CHM-like Rab escort protein (CHML; encoding Rep2) as an NRF2 target gene with an antioxidant response element (ARE) in its promoter region (-1622 to -1612). Analysis of patient data curated by The Cancer Genome Atlas (TCGA) and Oncomine databases revealed that CHML mRNA expression was elevated in lung adenocarcinoma (LUAD) patient tumor tissues and correlated with decreased patient survival. Immunohistochemistry (IHC) analysis of normal versus lung cancer patient tissues revealed that Rep2 protein levels were higher in lung tumors compared with normal tissue, which also correlated with increased levels of NRF2. Importantly, siRNA-mediated knockdown of CHML/Rep2 in A549 NSCLC cells decreased their ability to proliferate. Mechanistically, Rep2 mediates mTOR function, as loss of Rep2 inhibited, whereas overexpression enhanced, mTOR translocation and activation at the lysosome. Our findings identify a novel NRF2-Rep2-dependent regulation of mTOR function.
转录因子红系衍生 2 相关因子 2(NRF2)在非小细胞肺癌(NSCLC)中常高度表达。通过其靶基因,NRF2 增强了癌症的进展和化疗/放疗耐药性,导致高 NRF2 表达患者的预后更差。在这项研究中,我们鉴定出 CHM 样 Rab 衔接蛋白(CHML;编码 Rep2)作为 NRF2 的靶基因,其启动子区域(-1622 至-1612)存在抗氧化反应元件(ARE)。对癌症基因组图谱(TCGA)和 Oncomine 数据库中整理的患者数据进行分析表明,CHML mRNA 在肺腺癌(LUAD)患者肿瘤组织中表达上调,并与患者生存时间缩短相关。对正常与肺癌患者组织的免疫组织化学(IHC)分析表明,Rep2 蛋白水平在肺癌组织中高于正常组织,这也与 NRF2 水平的增加相关。重要的是,在 A549 NSCLC 细胞中用 siRNA 敲低 CHML/Rep2 会降低其增殖能力。从机制上讲,Rep2 介导 mTOR 功能,因为 Rep2 的缺失抑制了 mTOR 在溶酶体的易位和激活,而过表达则增强了这一过程。我们的发现确定了一种新型的 NRF2-Rep2 依赖性 mTOR 功能调节。